Lupin Ltd
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
- Market Cap ₹ 96,257 Cr.
- Current Price ₹ 2,107
- High / Low ₹ 2,403 / 1,774
- Stock P/E 18.0
- Book Value ₹ 596
- Dividend Yield 0.57 %
- ROCE 21.9 %
- ROE 17.8 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 28.2% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 24.1%
Cons
- Stock is trading at 3.53 times its book value
- The company has delivered a poor sales growth of 9.00% over past five years.
- Company has a low return on equity of 11.2% over last 3 years.
- Debtor days have increased from 101 to 122 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare BSE 100 BSE 200 BSE Dollex 200
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,939 | 9,752 | 11,344 | 12,626 | 10,081 | 11,356 | 11,026 | 11,056 | 11,772 | 11,259 | 14,666 | 16,968 | 18,471 | |
| 6,016 | 6,375 | 7,357 | 8,134 | 7,992 | 8,504 | 9,116 | 9,012 | 11,560 | 10,295 | 11,216 | 11,574 | 11,408 | |
| Operating Profit | 2,922 | 3,377 | 3,987 | 4,492 | 2,089 | 2,853 | 1,909 | 2,044 | 211 | 964 | 3,451 | 5,394 | 7,062 |
| OPM % | 33% | 35% | 35% | 36% | 21% | 25% | 17% | 18% | 2% | 9% | 24% | 32% | 38% |
| 405 | 177 | 187 | 82 | 128 | -49 | -286 | 129 | 215 | 210 | 115 | 176 | 744 | |
| Interest | 21 | 5 | 24 | 29 | 33 | 35 | 53 | 41 | 73 | 98 | 56 | 84 | 100 |
| Depreciation | 168 | 337 | 306 | 366 | 390 | 426 | 519 | 503 | 514 | 548 | 725 | 648 | 712 |
| Profit before tax | 3,139 | 3,212 | 3,844 | 4,179 | 1,794 | 2,342 | 1,052 | 1,630 | -162 | 527 | 2,785 | 4,837 | 6,994 |
| Tax % | 26% | 25% | 26% | 25% | 25% | 34% | 31% | 23% | 17% | 19% | 16% | 18% | |
| 2,324 | 2,397 | 2,831 | 3,141 | 1,345 | 1,539 | 728 | 1,259 | -189 | 425 | 2,326 | 3,973 | 5,761 | |
| EPS in Rs | 51.84 | 53.34 | 62.83 | 69.56 | 29.74 | 34.01 | 16.06 | 27.74 | -4.15 | 9.35 | 51.05 | 87.02 | 126.18 |
| Dividend Payout % | 12% | 14% | 12% | 11% | 17% | 15% | 37% | 23% | -96% | 43% | 16% | 14% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 9% |
| 3 Years: | 13% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 28% |
| 3 Years: | 173% |
| TTM: | 78% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 17% |
| 3 Years: | 41% |
| 1 Year: | -3% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 8% |
| 3 Years: | 11% |
| Last Year: | 18% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 90 | 90 | 90 | 90 | 90 | 90 | 91 | 91 | 91 | 91 | 91 | 91 | 91 |
| Reserves | 6,889 | 8,938 | 11,823 | 14,690 | 15,695 | 17,027 | 17,383 | 18,475 | 18,059 | 18,321 | 20,512 | 24,187 | 27,133 |
| 144 | 45 | 392 | 593 | 17 | 6 | 6 | 485 | 951 | 749 | 105 | 250 | 1,014 | |
| 1,675 | 1,935 | 1,931 | 2,475 | 2,879 | 2,567 | 3,201 | 2,808 | 3,212 | 3,523 | 4,215 | 3,904 | 4,423 | |
| Total Liabilities | 8,799 | 11,008 | 14,236 | 17,848 | 18,681 | 19,690 | 20,680 | 21,859 | 22,313 | 22,684 | 24,923 | 28,432 | 32,661 |
| 2,179 | 2,036 | 2,345 | 3,013 | 3,341 | 3,373 | 3,514 | 3,639 | 3,690 | 4,022 | 4,113 | 4,946 | 4,943 | |
| CWIP | 267 | 490 | 624 | 481 | 1,171 | 1,199 | 822 | 951 | 947 | 927 | 446 | 278 | 322 |
| Investments | 1,164 | 3,444 | 3,741 | 6,914 | 5,363 | 7,388 | 7,456 | 9,563 | 9,511 | 9,974 | 11,581 | 11,955 | 14,098 |
| 5,189 | 5,038 | 7,526 | 7,441 | 8,806 | 7,730 | 8,888 | 7,706 | 8,165 | 7,761 | 8,783 | 11,253 | 13,299 | |
| Total Assets | 8,799 | 11,008 | 14,236 | 17,848 | 18,681 | 19,690 | 20,680 | 21,859 | 22,313 | 22,684 | 24,923 | 28,432 | 32,661 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,528 | 2,852 | 917 | 4,352 | 209 | 3,111 | 2,219 | 1,570 | 151 | 1,794 | 2,504 | 2,445 | |
| -447 | -1,178 | -2,629 | -1,941 | 725 | -2,865 | -740 | -2,508 | -372 | -1,269 | -1,599 | -1,766 | |
| -844 | -221 | 17 | -160 | -987 | -295 | -368 | -53 | 102 | -498 | -867 | -460 | |
| Net Cash Flow | 237 | 1,452 | -1,696 | 2,252 | -52 | -50 | 1,112 | -991 | -118 | 27 | 38 | 218 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 117 | 94 | 146 | 113 | 179 | 120 | 120 | 105 | 84 | 87 | 96 | 122 |
| Inventory Days | 174 | 211 | 214 | 232 | 229 | 216 | 216 | 236 | 260 | 230 | 216 | 239 |
| Days Payable | 124 | 126 | 126 | 161 | 150 | 118 | 136 | 104 | 110 | 119 | 148 | 146 |
| Cash Conversion Cycle | 166 | 179 | 234 | 184 | 258 | 218 | 199 | 237 | 234 | 197 | 163 | 215 |
| Working Capital Days | 133 | 115 | 169 | 127 | 219 | 171 | 154 | 146 | 124 | 110 | 116 | 153 |
| ROCE % | 50% | 40% | 36% | 30% | 11% | 16% | 10% | 9% | -1% | 3% | 14% | 22% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
18 Dec - Dec 18, 2025: Lupin signs exclusive Plasil® licensing with Neopharmed for Philippines and Brazil; production shifts to MedQuimica.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
17 Dec - CHMP positive opinion for Lupin's Ranluspec ranibizumab; EC review pending; Sandoz to commercialize in EU (excluding Germany).
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
16 Dec - Received US FDA EIR (VAI) for Nagpur injectable facility; inspection Sept 8–16, 2025.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
16 Dec - SBTi validated Lupin GHG targets: Scope1/2 -42% by FY2030 (FY2023 base); Scope3 -61.07% by FY2033 (FY2024 base).
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
12 Dec - Dec 12, 2025: Lupin’s LMS and PolyPeptide form long-term alliance to scale peptide API supply chains globally.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
Concalls
-
Nov 2025Transcript PPT
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024TranscriptPPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Jan 2023TranscriptAI SummaryPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Jan 2022TranscriptAI SummaryPPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
May 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Jan 2021TranscriptAI SummaryPPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptPPT
-
Jun 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Jan 2020TranscriptAI SummaryPPT
-
Nov 2019TranscriptPPT
-
Nov 2019Transcript PPT
-
Aug 2019TranscriptAI SummaryPPT
-
May 2019TranscriptAI SummaryPPT
-
Feb 2019Transcript PPT
-
Jan 2019TranscriptAI SummaryPPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
Jun 2018TranscriptAI SummaryPPT
-
May 2018TranscriptAI SummaryPPT
-
Feb 2018TranscriptAI SummaryPPT
-
Jan 2018TranscriptAI SummaryPPT
-
Nov 2017Transcript PPT
-
Sep 2017TranscriptAI SummaryPPT
-
Aug 2017TranscriptAI SummaryPPT
-
May 2017TranscriptAI SummaryPPT
-
Feb 2017TranscriptAI SummaryPPT
-
Jan 2017TranscriptAI SummaryPPT
-
Nov 2016TranscriptAI SummaryPPT
-
Jun 2016TranscriptPPT
Products
Co. is engaged in developing and marketing generic formulations, biotechnology products, and APIs globally. Co. has a significant presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, and Central Nervous system, among other segments, and is a global leader in e Anti-TB and Cephalosporins segments. [1]